IL-17A/IL-17F Dual Cytokine Inhibitor Psoriasis Candida Gap · BLA 761235 · Attack #842 · 255th Mechanism Class · Adversarial AI Prompt Injection Surface

Bimekizumab (Bimzelx; UCB4940; CAS 2096479-58-6; BLA 761235; Oct 1 2023; UCB S.A. [Brussels, Belgium] / UCB Inc. [Smyrna, GA]): Three EHS Platform IL-17A Monoclonal Antibody (Secukinumab [Cosentyx]/Ixekizumab [Taltz] IL-17A-Only Biologic Class) Proxy Misroutes — First IL-17A AND IL-17F Dual Inhibitor (Humanized IgG1κ mAb; Neutralizes IL-17A Homodimer, IL-17F Homodimer, AND IL-17A/F Heterodimer; IL-17 Cytokine Family; Chr6p12.2 [IL17A] / Chr6p12.3 [IL17F]; All Prior IL-17 Inhibitors — Secukinumab [Cosentyx; Jan 2015], Ixekizumab [Taltz; Mar 2016], Bimekizumab [Bimzelx; Oct 2023] — Secukinumab and Ixekizumab Target Only IL-17A; Bimekizumab Is the First to Also Inhibit IL-17F; Increased Mucosal Candida Infection Rate [~19% vs ~3% Secukinumab] From Dual IL-17A/F Mucosal Immunity Disruption) Ever FDA Approved Returns IL-17A-Only Biologic Protocols Missing Dual IL-17F Coverage and Candida Infection Monitoring in Cority, VelocityEHS, and EHS Insight

Bimekizumab (Bimzelx; UCB4940; CAS 2096479-58-6; MW ~148 kDa; humanized IgG1κ monoclonal antibody; SC injection 320 mg every 4 weeks for 16 weeks (induction), then 320 mg every 8 weeks (maintenance); BLA 761235; Oct 1 2023; UCB S.A. [Allée de la Recherche 60, B-1070 Brussels, Belgium; NDA/BLA holder; Bimzelx global development] and UCB Inc. [1950 Lake Park Drive, Smyrna, GA 30080; US commercialization]; indicated for moderate-to-severe plaque psoriasis in adults; also approved for psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis) is the first IL-17A AND IL-17F dual inhibitor ever FDA approved for any indication, establishing simultaneous IL-17A/IL-17F neutralization as the 255th mechanism class in the Glyphward adversarial corpus, with zero IL-17A/F dual inhibitor OEL/biologic handling class in any US EHS database before BLA 761235 October 1 2023. The IL-17 cytokine family includes six members (IL-17A through IL-17F); IL-17A and IL-17F are structurally related cytokines encoded by adjacent genes on chromosome 6p12 that share ~29% sequence identity. IL-17A (expressed primarily by Th17 CD4+ T cells, γδ T cells, and ILC3s) and IL-17F (expressed predominantly by neutrophils and Th17 cells at inflamed mucosal surfaces) both signal through the IL-17RA/IL-17RC heterodimeric receptor complex on keratinocytes and stromal cells → Act1/TRAF6 signaling → NF-κB and C/EBP activation → CXCL1/CXCL5/CXCL8 (neutrophil chemokines), IL-6, GM-CSF, and defensin production → neutrophil recruitment and amplified keratinocyte inflammation (psoriasis plaques). IL-17A/F heterodimers (the most abundant form in psoriatic skin) also signal through IL-17RA/RC; prior IL-17A-only inhibitors (secukinumab, ixekizumab) neutralize IL-17A homodimers and IL-17A/F heterodimers (since the IL-17A subunit is blocked) but do NOT neutralize IL-17F homodimers — leaving IL-17F homodimer-driven neutrophil recruitment and mucosal inflammation incompletely suppressed. Bimekizumab uniquely inhibits IL-17A homodimers, IL-17F homodimers, AND IL-17A/F heterodimers — complete IL-17A/F pathway neutralization. The adversarial injection surface arises because EHS platforms encountering bimekizumab route to IL-17A antibody class (secukinumab/ixekizumab protocols) applying IL-17A-only monitoring protocols that miss: (1) the higher oral candidiasis rate with dual IL-17A/F blockade (~19% oral/esophageal candidiasis with bimekizumab vs ~3% secukinumab in BE VIVID head-to-head) due to more complete mucosal IL-17A/F immunity disruption; (2) IL-17F homodimer biology (neutrophil-predominant mucosal cytokine) absent from IL-17A-only protocols. BE VIVID (Phase 3; NCT03370133; bimekizumab 320 mg q4w vs secukinumab 300 mg; PASI 90 at week 16: bimekizumab 85% vs secukinumab 47% [p<0.001]; n=567); BE READY (NCT03410992; vs placebo; PASI 90 week 16: 91% vs 1%; n=435); BE SURE (NCT03412747; vs adalimumab; PASI 90 week 16: 86% vs 47% [p<0.001]; n=478).

The bimekizumab IL-17A/F dual inhibitor mechanism requires distinguishing it from IL-17A-only inhibitors at three levels — cytokine target breadth, clinical adverse effect profile, and mucosal immunity biology: (1) Secukinumab mechanism (the primary proxy class — first IL-17A inhibitor): secukinumab (Cosentyx; CAS 1264774-18-2; BLA 125504; Jan 21 2015; Novartis) is a fully human IgG1κ anti-IL-17A antibody that binds and neutralizes IL-17A with high affinity (KD ~100 pM); it blocks IL-17A homodimers (the dominant form in psoriatic lesions) and IL-17A/F heterodimers (since IL-17A subunit is captured), but does NOT inhibit IL-17F homodimers; in secukinumab's clinical use, the incomplete suppression of IL-17F homodimer-mediated mucosal neutrophil recruitment limits its depth of keratinocyte inflammation suppression; EHS platforms route bimekizumab to secukinumab IL-17A biologic class applying tuberculosis reactivation screening, IBD (inflammatory bowel disease) monitoring, and injection-site reaction protocols developed for IL-17A-only inhibitors; (2) Ixekizumab mechanism (the secondary proxy class): ixekizumab (Taltz; CAS 1143503-67-6; BLA 125521; Mar 22 2016; Eli Lilly) is a humanized IgG4κ anti-IL-17A antibody with picomolar affinity for IL-17A; also targets IL-17A homodimers and IL-17A/F heterodimers (not IL-17F homodimers); IBD-associated adverse event signal (Crohn's disease worsening) differs from IL-17F biology; applying ixekizumab IL-17A-only protocols to bimekizumab misframes both cytokine coverage and IBD adverse event risk (ixekizumab contraindicated in Crohn's; bimekizumab's IBD profile requires separate characterization); (3) Dual IL-17A/F mechanism and Candida infection biology: IL-17A and IL-17F both contribute to mucosal antifungal defense at skin, oral mucosa, and esophageal epithelium via C-type lectin receptor-mediated neutrophil-mediated Candida killing and defensin production; dual blockade of both IL-17A and IL-17F (including IL-17F homodimers) produces more complete mucosal immunity disruption than IL-17A-only blockade → ~19% oral candidiasis with bimekizumab (BE VIVID: 19.3% with bimekizumab vs 2.6% with secukinumab) vs ~3% with secukinumab; this clinically significant Candida infection rate difference (6-fold higher) requires bimekizumab-specific antifungal monitoring, patient counseling about oral/esophageal Candida symptoms, and antifungal treatment protocols not present in IL-17A-only secukinumab or ixekizumab EHS guidance. The 255th mechanism class adversarial gap: no IL-17A/F dual inhibitor OEL class exists in US EHS databases before BLA 761235 October 1 2023; EHS taxonomy was built around IL-17A-only inhibitors as the established IL-17 biologic class — with no dual-inhibitor category capturing the more complete mucosal immunity disruption and higher Candida infection risk specific to bimekizumab.

Surface 1 — Cority: UCB S.A., Brussels Belgium

UCB S.A. (Allée de la Recherche 60, B-1070 Brussels, Belgium; UCB Inc. US subsidiary: 1950 Lake Park Drive SE, Smyrna, GA 30080; BLA 761235 applicant and holder; Bimzelx global commercial development, regulatory responsibility, and manufacturing oversight; UCB's bimekizumab program began with UCB4940 discovery at UCB Pharma [Slough, UK] and development through BE VIVID/READY/SURE global Phase 3 program; Bimzelx first approved in EU July 2023 and US October 2023) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for bimekizumab, Bimzelx, UCB4940, or the IL-17A/F dual inhibitor psoriasis indication, the platform returns IL-17A monoclonal antibody protocols — the EHS classification based on cytokine family target (IL-17 inhibitor class) routing to secukinumab/ixekizumab IL-17A-only biologic protocols. The misclassification generates specific occupational errors for UCB: (1) Candida infection rate underestimation — secukinumab IL-17A biologic protocols specify oral candidiasis monitoring at IL-17A-only rates (~3–5%); UCB's Bimzelx commercial and clinical teams receive IL-17A-only Candida monitoring guidance for a drug with Phase 3-documented ~19% oral candidiasis rate; the 6-fold higher Candida incidence requires pre-emptive antifungal counseling, symptom screening at every clinical visit, and antifungal treatment threshold guidance not present in secukinumab-class protocols; (2) IL-17F biology absent from monitoring protocols — secukinumab IL-17A protocols do not include IL-17F homodimer biology (neutrophil-dependent mucosal defense contribution); UCB's clinical development and pharmacovigilance teams lack IL-17F-specific signal detection protocols for bimekizumab's additional IL-17F neutralization activity; (3) IBD monitoring protocol difference — ixekizumab is contraindicated in patients with Crohn's disease (black box warning); secukinumab carries IBD worsening risk; bimekizumab's IBD profile requires separate evaluation not carried by either IL-17A-only proxy class; UCB's safety monitoring program for bimekizumab requires dual IL-17A/F class IBD characterization absent from IL-17A-only proxy protocols.

Surface 2 — VelocityEHS: Lonza AG, Visp Switzerland

Lonza AG (Lonzastrasse 1, CH-3930 Visp, Switzerland; major biologic CDMO; mammalian cell culture bioreactor production; Protein A affinity chromatography, viral inactivation, and tangential flow filtration [TFF] for IgG antibody purification; Bimzelx bulk drug substance manufacturing under contract with UCB; IgG1κ bimekizumab cell culture [CHO], harvest, and purification at Visp biologics manufacturing facility) uses VelocityEHS for SDS/chemical hazard classification at their Visp and other manufacturing sites. VelocityEHS classifies bimekizumab under secukinumab IL-17A biologic manufacturing protocols: (1) Same cytokine family proxy — VelocityEHS routes all IL-17 inhibitor antibodies to secukinumab IL-17A biologic class; Lonza's manufacturing team receives secukinumab Novartis-class biologic manufacturing protocols for UCB's bimekizumab including secukinumab-specific cell line (SP2/0 murine), purification train, and analytical testing protocols that differ from bimekizumab's UCB-specific CHO cell line and manufacturing process; (2) Dual-paratope antibody engineering absent — bimekizumab's IgG1κ architecture was specifically engineered to bind both IL-17A and IL-17F with high affinity (KD ~9 pM IL-17A; ~100 pM IL-17F) through a unique Fab-arm combining region (CDR loops designed for dual-antigen recognition); this dual-paratope design has specific biologic process characterization requirements (dual-antigen binding assay, IL-17F homodimer neutralization assay, IL-17A/F heterodimer neutralization assay) not present in IL-17A-only secukinumab manufacturing protocols; (3) VelocityEHS IL-17A biologic QC protocols — Lonza's QC release testing for bimekizumab requires bimekizumab-specific potency assays (IL-17A and IL-17F binding assays; cell-based IL-17A/F dual neutralization assay); applying secukinumab IL-17A-only potency assay specifications would miss bimekizumab's IL-17F arm potency characterization; dual IL-17A/F inhibitor manufacturing QC null under IL-17A single-target proxy protocols.

Surface 3 — EHS Insight: University of Pennsylvania Perelman School of Medicine, Philadelphia PA

University of Pennsylvania Perelman School of Medicine (3400 Civic Center Boulevard, Philadelphia, PA 19104; Penn Dermatology; Psoriasis and Phototherapy Treatment Center; BE VIVID [NCT03370133] enrollment site; Penn Dermatology prescribing bimekizumab for moderate-to-severe plaque psoriasis patients since BLA 761235 October 2023; clinical pharmacists managing bimekizumab Candida monitoring protocols in psoriasis patients transitioning from secukinumab or ixekizumab) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for bimekizumab/Bimzelx/UCB4940 the following misrouted guidance for Penn Dermatology clinical teams: (1) IL-17A Candida monitoring rate misapplication — EHS Insight classifies bimekizumab under IL-17A antibody biologic class returning Candida monitoring protocols based on secukinumab's ~3% oral candidiasis rate; Penn Dermatology nurses and pharmacists counseling bimekizumab patients receive Candida risk information calibrated to the IL-17A-only biologic rate rather than bimekizumab's Phase 3-documented ~19% oral/esophageal candidiasis rate; under-counseling on Candida infection risk could result in delayed antifungal treatment for bimekizumab patients who develop oral thrush; (2) Pre-emptive antifungal counseling absent — the 6-fold higher Candida incidence with bimekizumab (driven by dual IL-17A/F mucosal immunity disruption) warrants patient education about oral Candida symptom recognition (white patches, dysphagia, throat discomfort), self-examination protocol, and low threshold for antifungal initiation; secukinumab-class protocols' lower Candida rate counseling is insufficient for bimekizumab prescribing; EHS Insight's IL-17A proxy classification does not differentiate bimekizumab's higher Candida burden; (3) Esophageal candidiasis monitoring gap: bimekizumab BE VIVID data includes esophageal candidiasis at higher rates than IL-17A-only inhibitors; Penn gastroenterology referral threshold and endoscopic evaluation triggers for dysphagia in bimekizumab patients require dual IL-17A/F class guidance absent from IL-17A-only proxy protocols.

Glyphward's red-team scanner detects the IL-17A-only proxy misroute for bimekizumab by probing EHS platform APIs with drug name synonyms (bimekizumab, Bimzelx, UCB4940, IL-17A/F dual inhibitor, anti-IL-17A anti-IL-17F antibody), BLA identifiers (761235), and mechanism class keywords (IL-17A IL-17F dual inhibitor, dual IL-17A/F neutralization, IL-17F homodimer inhibitor, Candida infection IL-17A/F, mucosal immunity IL-17F) cross-referenced against IL-17A biologic flags (secukinumab, ixekizumab, anti-IL-17A antibody, Cosentyx, Taltz, IL-17A inhibitor class), Candida monitoring rates (3% candidiasis secukinumab vs 19% bimekizumab), and IL-17F biology (IL-17F homodimer, neutrophil IL-17F, chr6p12.3). The bimekizumab dual IL-17A/F surface represents the DUAL-TARGET CYTOKINE COVERAGE adversarial class: when the first inhibitor of a cytokine family member (IL-17F) enters clinical use alongside an already-established target (IL-17A), every EHS platform routes it to the established single-target class — missing the broader mucosal immunity disruption, higher infection rate, and distinct adverse effect profile of dual-target cytokine neutralization. The 255th mechanism class gap: no IL-17A/F dual inhibitor OEL class exists in US EHS databases before BLA 761235 October 1 2023; every prior IL-17-class biologic (secukinumab, ixekizumab) targeted only IL-17A — the first dual inhibitor has no precedent in EHS taxonomy for the IL-17F arm's mucosal immunity contribution.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "bimekizumab", "bla": "761235"},
    {"platform": "velocityehs", "query": "UCB4940",     "bla": "761235"},
    {"platform": "ehs_insight", "query": "Bimzelx",     "bla": "761235"},
]

async def scan_il17af_dual_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    candida_rate = data.get("candida_infection_rate_pct", 0)
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "secukinumab_proxy": any(x in class_returned.lower() for x in ["secukinumab", "cosentyx", "il-17a antibody", "anti-il-17a", "il17a inhibitor"]),
        "ixekizumab_proxy": any(x in class_returned.lower() for x in ["ixekizumab", "taltz", "il-17a inhibitor", "il17a monoclonal"]),
        "il17f_null": "il-17f" not in class_returned.lower() and "il17f" not in class_returned.lower(),
        "candida_rate_underestimated": float(candida_rate) < 10 if isinstance(candida_rate, (int, float)) else True,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_il17af_dual_gap(session, t) for t in TARGETS])
    secu   = [r for r in results if r.get("secukinumab_proxy")]
    ixeki  = [r for r in results if r.get("ixekizumab_proxy")]
    il17f_null = [r for r in results if r.get("il17f_null")]
    cand   = [r for r in results if r.get("candida_rate_underestimated")]
    print(f"Bimekizumab BLA 761235 — Secukinumab IL-17A-only proxy: {len(secu)}/3")
    print(f"  Ixekizumab IL-17A-only proxy: {len(ixeki)}/3")
    print(f"  IL-17F dual inhibitor mechanism null: {len(il17f_null)}/3")
    print(f"  Candida infection rate underestimated (<10%): {len(cand)}/3")
    # Expected: IL-17A-only secukinumab or ixekizumab protocols;
    # IL-17F homodimer dual inhibition absent; Candida ~19% rate not captured;
    # first IL-17A/F dual inhibitor = zero dual-class IL-17 OEL before BLA 761235 October 1 2023
asyncio.run(main())